In the initial Phase III study , hemo - or peritoneal dialysis patients with hyperphosphatemia were randomized 2:1 to receive sucroferric oxyhydroxide 1.0-3 .0 g/day ( 2-6 tablets/day ; n = 710 ) or sevelamer 2.4-14 .4 g/day ( 3-18 tablets/day ; n = 349 ) for 24 weeks .